Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247012 | 0.80 | ALDH1A1 (0.50) | ALDH1A1KDM4ECA12CA1CA2 | |
| SCHEMBL5745307 | 0.79 | GAA (0.55) | ALDH1A1LMNAGAACA12CA1 | |
| SCHEMBL4074745 | 0.79 | ENPP2 (0.45) | TP53SMN1; SMN2 | |
| SCHEMBL1169954 | 0.79 | ALDH1A1 (0.55) | ALDH1A1MAPTLMNAGAACA12 | |
| SCHEMBL10180779 | 0.78 | GAA (0.59) | ALDH1A1MAPTLMNAKDM4EGAA | |
| SCHEMBL17376401 | 0.77 | MMP3 (0.50) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL7118736 | 0.76 | CA2 (0.52) | ALDH1A1MAPTGAACA12CA1 | |
| SCHEMBL4079205 | 0.75 | F2 (0.41) | MAPTCA12CA1CA2CA9 | |
| SCHEMBL2320786 | 0.75 | PSEN1 (0.46) | ALDH1A1CA1CA2TP53PKM | |
| SCHEMBL22057007 | 0.75 | MAPT (0.53) | ALDH1A1MAPTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024928-A1 | 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES | BioVersys AG (CH) | 2022-01-27 | — | — | US | disclosed |
| US-9303042-B2 | Triazolothienopyrimidine compound inhibitors of urea transporters and methods of using inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-04-05 | — | — | US | disclosed |
| WO-2013148813-A1 | TRIAZOLOTHIENOPYRIMIDINE COMPOUND INHIBITORS OF UREA TRANSPORTERS AND METHODS OF USING INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-03 | — | — | WO | disclosed |
| EP-1625112-B1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20060128662-A1 | Novel compounds for treatment of obesity | NOVO NORDISK A/S (DK) | 2006-06-15 | — | — | US | disclosed |
| EP-1625112-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004101505-A1 | NOVEL COMPOUNDS FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-11-25 | — | — | WO | disclosed |
| CN-1118468-C | Pyrazolopyrimidines and pyrazolotriazines | HOFFMANN LA ROCHE (CH) | 2003-08-20 | — | — | CN | disclosed |
| EP-0941994-B1 | Pyrazolopyrimidines and pyrazolotriazines with 5-HT6 receptor affinity | HOFFMANN LA ROCHE (CH) | 2003-05-14 | — | — | EP | disclosed |
| US-6194410-B1 | ANTISEROTONINE AGENTS; NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS | HOFFMAN-LA ROCHE INC. | 2001-02-27 | — | — | US | disclosed |
| CN-1236780-A | Pyrazolopyrimidines and pyrazolotriazines | HOFFMANN LA ROCHE (CH) | 1999-12-01 | — | — | CN | disclosed |
| EP-0941994-A1 | Pyrazolopyrimidines and pyrazolotriazines with 5-HT6 receptor affinity | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024928-A1 | 3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES | OR10J3, ORC3, CBR3 | ALDH1A1 1547/4885MAPT 4658/4885LMNA 3949/4885 |
| US-20060128662-A1 | Novel compounds for treatment of obesity | GPR119, FABP4, HSD17B4 | ALDH1A1 66/4885MAPT 4680/4885LMNA 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.